pharma industry trends ppt2
TRANSCRIPT
-
8/2/2019 Pharma Industry Trends Ppt2
1/20
Pharma Industry Trends
IVth Year B. Pharm. + MBA Pharmtech
Lecture 2 : March 2012
Indian Healthcare Market
-
8/2/2019 Pharma Industry Trends Ppt2
2/20
Total Pharma 53,803 100.00 +15
Rank CompanyValue
(Rs cr.) M.S. %Growth
+/-%1 Abbott 3,855 7.16 +20
2 Cipla 2,723 5.06 +12
3 Ranbaxy 2,524 4.69 +16
4 GSK 2,166 4.02 +9
5 Sun Pharma 2,100 3.90 +226 Zydus Cadila 1,970 3.66 +13
7 Mankind 1,815 3.37 +23
8 Alkem 1,795 3.34 +16
9 Pfizer 1,719 3.20 +16
10 Lupin 1,449 2.69 +14
11 Mcleods 1,350 2.51 +43
12 Intas 1,306 2.43 +2813 Sanofi 1,283 2.38 +16
14 Aristo 1,199 2.23 +7
15 Emcure 1,127 2.09 +18
16 Dr Reddys 1,091 2.03 +8
17 Torrent 1,079 2.00 +16
18 Wockhardt 1,075 2.00 +16
19 USV 979 1.82 +24
20 Micro Labs 949 1.76 +15
Rank Company
1 Abbott
2 Cipla
3 Sun Pharma
4 Zydus Cadila5 GSK
January 2012 rankings
-
8/2/2019 Pharma Industry Trends Ppt2
3/20
Rank Brand Company Value(Rs cr.) M.S. Growth+/-%1 Corex Pfizer 237 0.44 +16
2 Human Mixtard Abbott 223 0.41 +21
3 Phensedyl Abbott 208 0.39 +20
4 Voveran Novartis 198 0.37 +9
5 Augmentin GSK 196 0.36 +146 Revital Ranbaxy 196 0.34 +14
7 Monocef Aristo 184 0.32 +11
8 Dexorange Franco India 171 0.30 +10
9 Taxim Alkem 162 0.28 +3
10 Liv-52 Himalaya 152 0.28 +10
11 Volini Ranbaxy 148 0.27 +51
12 Mox Ranbaxy 147 0.27 +813 Spasmo Proxyvon Wockhardt 146 0.27 +34
14 Becosules Pfizer 143 0.27 -5
15 Betadine Win Medicare 138 0.26 +14
16 Zifi Fulford 137 0.25 -6
17 Asthalin Cipla 132 0.25 +4
18 Clavam Alkem 124 0.23 +23
19 Calpol GSK 123 0.23 +12
20 Taxim-O Alkem 122 0.23 +7
Jan 12
Rank
1
2
5
4
3
-
8/2/2019 Pharma Industry Trends Ppt2
4/20
Top 10 Therapeutic Groups2011
Rank 2011 Supergroup Share of Pharma Value Gr1 Anti-infectives 18% +13%
2 Cardiac 11% +15%
3 Gastro Intestinal 11% +16%4 Pain/Analgesic 8% +14%
5 Respiratory 8% +10%
6 Vitamins/Minerals 7% +13%
7 Anti Diabetic 6% +23%
8 Gynaec 6% +12%
9 Neuro/CNS 6% +16%
10 Derma 5% +15%
86%
-
8/2/2019 Pharma Industry Trends Ppt2
5/20
The Pharma Growth Drivers in India
India is one of the fastest-growing pharma industries
globally
Primarily driven by a large population
Evolving patient demographics
Increasing health care expenditure Growing urbanisation
Rising life expectancy and
Active private-sector participation in all sectors of
Indian Healthcare
-
8/2/2019 Pharma Industry Trends Ppt2
6/20
6
Higher the Value Curve Better Pricing Advantage
Low
High
Intermediate
& Bulk
Substances
Commodity
Generics
Conventional
Dosage Forms
Value- Added and
Branded Generics
OTC & New Drug
Delivery Systems
New Chemical
Entity & Drug
Discovery
Tech
nological/Marketin
gComplexity
Bottom Line
-
8/2/2019 Pharma Industry Trends Ppt2
7/20
The Scene ShiftsThe global pharmaceuticals market grew rapidly in the 1990s and in the early
2000s, spurred primarily by market demand in North America and Europe.
However:
With impeding patent expiries
Declining R&D productivity
Increasing regulatory and pricing pressures
growth in these markets have been slowing down.
Emerging markets represent a potential growth driver for the industry its
contribution to the growth of the global pharma market increased from eightper cent in 2003 to 40 per cent in recent times.
Consequently, global pharma MNCs have adopted prudent strategies to
further expand their footprint in emerging markets such as Brazil, Russia,
India and China.
-
8/2/2019 Pharma Industry Trends Ppt2
8/20
The way forward for India
Formulations manufactured in India
Constitute 20 per cent of the global generics market by value and
The overall share of Indian manufactured formulations is as high as 46
per cent in the generics segment in the emerging markets.
Opportunities exist ranging from the low-value added segment,
comprising of NDDS ($134 billion opportunity by 2013)
Generics ($135 billion worth of product expiring before 2015) and
Biosimilars ($115 billion worth of biologics expiring by 2015)
High value New Chemical Entity (NCE)/New Biopharmaceutical Entitysegment.
Thus, domestic companies can look forward to pursue all these
opportunities and build capabilities to conduct drug discovery and in
house development.
-
8/2/2019 Pharma Industry Trends Ppt2
9/20
Projections for the
Indian Pharma Market
Indian pharmaceutical market by 2020 (US $billion)
-
8/2/2019 Pharma Industry Trends Ppt2
10/20
Increasing number of patented
drugs launched in India
Pharma MNCs are projected to capture a 35 per cent market share of the market by
2017, compared with 28 per cent in 2009.
Over the years, pharma MNCs have adopted India-focused strategies to tap the
growing potential of the countrys pharma market.
The advent of the product patent regime in 2005 instilled confidence in the countrys
IP regime. With renewed confidence, large pharma MNCs are now looking to launch
their patented drugs in India and such product launches are expected to increase
further in future.
-
8/2/2019 Pharma Industry Trends Ppt2
11/20
Pharma MNCs : Adopting inorganic
route to enhance presenceMNCs have acquired domestic players to gain sizeable share inthe domestic market.
These acquisitions have also enabled pharma MNCs to access the
infrastructure, distribution networks, and managementcapabilities of domestic players, thereby strengthening their
business operations in the country.
Licensing agreements with Indian companies have helped pharma
MNCs access a ready basket of generic products.
These deals are likely to accelerate the launch of products in
various emerging markets while offering MNCs the advantage of
cost-effective manufacturing.
-
8/2/2019 Pharma Industry Trends Ppt2
12/20
Pharma MNCs : Adopting inorganic
route to enhance presencecontd.
Pharma MNCs consider India as a preferred strategic
outsourcing partner with services ranging from:
Contract Research Manufacturing (CRO) and
Clinical research services to sales and marketing,
Information technology,
Finance and accounting, and
Customer-relationship management.
-
8/2/2019 Pharma Industry Trends Ppt2
13/20
Pharma MNCs :Changing the tune for India
Differential pricing strategy to strengthen market reach:
In a bid to compete with domestic generic players, pharma MNCs are
launching patent-protected drugs in India at relatively low price points
than those in developed markets.
Simultaneously, a differential pricing strategy is helping these MNCs to
enhance their market reach by addressing affordability issues.
Drugs such as Diovan (for bp, Novartis), Januvia (for type II diabetes,
Merck Sharp & Dohme), and Galvus (also for Type II diabetes,
Novartis) are being sold at discounts of up to 80 per cent on global
prices.
-
8/2/2019 Pharma Industry Trends Ppt2
14/20
Rural-centric initiatives to
enhance market accessRobust consumption in the rural economy is expected to be a key
growth driver. Rural India accounts for more than 70 per cent of
all Indian households and close to 40 per cent of the totalconsumption pie. Henceforth, a large number of companies are
organising their efforts to derive a major portion of their overall
sales from this untapped market.
Additionally, pharma MNCs are looking to implement new andeffective business models in India and improve the health of
patients. Delivering patient health outcomes implies getting
involved in the cycle of care, rather than just delivering drugs to a
health care system.
-
8/2/2019 Pharma Industry Trends Ppt2
15/20
A few examples include:
In 2009, Sanofi-Aventis launched the Saath 7 programme in India, inwhich certified counsellors help diabetic patients understand their diseases
and provide personalised consultation through home visits.
In 2009, Mercks Indian subsidiary, MSD Pharmaceuticals,launched Sparsh, a multilingual helpline for diabetics on its drugs Januvia
and Janumet to provide diet, exercise, and adherence advice.
In September 2010, Johnson & Johnson (J&J) launched a mobile healthinitiative for expectant mothers in India. Mobile Health for Mothers
provides free text messages on prenatal care, appointment reminders and
calls from health coaches.
Rural initiatives by MNCs
-
8/2/2019 Pharma Industry Trends Ppt2
16/20
Rural initiatives by MNCscontd.
In July 2011, Pfizer collaborated with FMCG major ITCto enhance its product sales in the rural markets. According to
the agreement, Pfizer will sell its over-the-counter products
through ITC channels in rural areas.
Such noble initiatives can be expected to help pharma MNCs
further augment their brand awareness in the domestic
market and help tap the segments growth potential.
-
8/2/2019 Pharma Industry Trends Ppt2
17/20
Shifting Disease Burden in India
Shifting disease burden in India
-
8/2/2019 Pharma Industry Trends Ppt2
18/20
Favourable demographics and
changing disease patterns
This is contributing to the increasing demand.
India has witnessed rapid epidemiological transition as a consequence of
economic and social change.
Historically, acute disease segments have dominated the market, with the anti-
infective sub-segment contributing a major share. However, with growing
urbanisation, the disease profile of the Indian population has become
increasingly skewed toward lifestyle-related ailments such as obesity, heart
disease, stroke, cancer, diabetes and respiratory diseases.
The number of people suffering from chronic diseases such as cancer,
diabetes, neuropsychiatric conditions and cardiovascular disease is setto double in India by 2020. Thus, change in patient demographics will fuel
demand for quality and affordable products in the domestic market.
-
8/2/2019 Pharma Industry Trends Ppt2
19/20
Expanding healthcare infrastructure and
changing demographics to supplement growth
The Indian healthcare sector is forecast to reach $280 billion by 2020,contributing expected GDP expenditure of eight per cent by 2012,
compared with 4.2 per cent in 2009, according to a report by an industry body.
Over the past two decades, Indias thriving economy has driven the need for
urbanisation, thereby creating an expanding middle class with increaseddisposable income to spend on healthcare.
Other key growth drivers for this sector include a growing population, the
opening of new hospitals, growing lifestyle related health issues, less expensive
treatment costs, the growth of medical tourism, improving health insurancepenetration and government initiatives.
The overall growth of the Indian healthcare sector is likely to create a sizeable
demand for quality and affordable medicines, thereby providing significant
growth opportunities for both domestic and pharma MNCs.
-
8/2/2019 Pharma Industry Trends Ppt2
20/20